Data on Rexahn’s Anticancer Small Molecule to be Presented at AACR Conference

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

These data on the anti-cancer activity of RX-8243 will be presented in a poster (abstract #3562) entitled, “Characterization of a novel small molecule with potent anticancer activity,” on Tuesday, April 20, 2010, from 9:00 am – 12:00 pm EDT in Exhibit Hall A-C, Poster Section 24, during the “Experimental and Molecular Therapeutics” session.

RX-8243 is a novel isoquinolinamine analogue that inhibits Ark1 (Aurora A) kinase and other Ser/Thr kinases implicated in cancer progression. RX-8243 is a multikinase inhibitor that down-regulates signal molecules of RAS as well as PI3K pathways such as activated forms of ERK, p38 and Akt. Pre-clinical studies demonstrated that RX-8243 blocked tumor growth in xenograft models at low nanomolar concentrations. These studies also have shown RX-8243 to be more effective against paclitaxel, gemcitabine and cisplatin-resistant cancer cell lines when compared to the original cytotoxic cancer drugs. RX-8243 is part of a robust pipeline of pre-clinical anti-cancer compounds that Rexahn has developed to provide higher efficacy and to improve the quality of life and survival of patients.

Source: http://www.rexahn.com/